Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q2 2026
184
Period ended Jun 30, 2026
Change on a year earlier
+42.6%
129 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
2
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 184 | +42.6% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 142 | +32.7% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 279 | +458.0% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 244 | +151.5% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 129 | +158.0% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 107 | +127.7% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 50 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2024 | Sep 30, 2024 | 97 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q2 2024 | Jun 30, 2024 | 50 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q1 2024 | Mar 31, 2024 | 47 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
Breakdown
What makes up capvaxive (21-valent adult pneumococcal conjugate vaccine, launched q2 2024) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_capvaxive
See every metric in the Merck KPI table. Data updated Oct 26, 2026.